Exhibitor

VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs. We have two approved therapies and one product candidate in clinical development. Qsymia® (phentermine and topiramate extended release) is approved by FDA for chronic weight management. STENDRA® (avanafil) is approved for erectile dysfunction by FDA and by the EC under the trade name SPEDRA. Tacrolimus is in clinical development for the treatment of patients with pulmonary arterial hypertension.